Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Clin Exp Pharmacol Physiol ; 43(6): 612-5, 2016 06.
Article in English | MEDLINE | ID: mdl-27009880

ABSTRACT

This study tested the hypothesis that the initial fall in arterial pressure evoked by lipopolysaccharide (LPS) is mediated by the ventrolateral column of the midbrain periaqueductal gray region (vlPAG). To test this hypothesis, the local anaesthetic lidocaine (2%; 0.1 µL, 0.2 µL or 1.0 µL), the delta opioid receptor antagonist naltrindole (2 nmol) or saline was microinjected into the vlPAG of isoflurane-anaesthetized rats bilaterally and LPS (1 mg/kg) or saline was administered intravenously 2 min later. Both lidocaine and naltrindole inhibited LPS-evoked hypotension significantly but did not affect arterial pressure in saline-treated control animals. Neither lidocaine nor naltrindole altered heart rate significantly in either LPS-treated or control animals. Microinjection of lidocaine or naltrindole into the dorsolateral PAG was ineffective. These data indicate that the vlPAG plays an important role in the initiation of endotoxic hypotension and further show that delta opioid receptors in the vlPAG participate in the response.


Subject(s)
Arterial Pressure/drug effects , Arterial Pressure/physiology , Lipopolysaccharides/administration & dosage , Periaqueductal Gray/drug effects , Periaqueductal Gray/physiology , Animals , Endotoxins/administration & dosage , Injections, Intraventricular , Male , Rats , Rats, Sprague-Dawley
2.
Neuropeptides ; 58: 23-9, 2016 Aug.
Article in English | MEDLINE | ID: mdl-26861257

ABSTRACT

Glycyl-L-glutamine (Gly-Gln; ß-endorphin30-31) is an endogenous dipeptide synthesized through the post-translational processing of ß-endorphin1-31. Central Gly-Gln administration inhibits the rewarding properties of morphine and attenuates morphine tolerance, dependence and withdrawal although it does not interfere with morphine analgesia. In an earlier study, we found that Gly-Gln inhibits morphine-induced dopamine efflux in the nucleus accumbens (NAc), consistent with its ability to inhibit morphine reward. To further investigate the mechanism responsible for its central effects we tested whether i.c.v. Gly-Gln administration influences the rise in extracellular serotonin and GABA concentrations evoked by morphine in the NAc. Conscious rats were treated with Gly-Gln (100nmol/5µl) or saline i.c.v. followed, 2min later, by morphine (2.5mg/kg) or saline i.p. and extracellular serotonin and GABA concentrations were analyzed by microdialysis and HPLC. Morphine administration increased extracellular serotonin and GABA concentrations significantly within 20min, as shown previously. Unexpectedly, Gly-Gln also increased extracellular serotonin concentrations significantly in control animals. Combined treatment with Gly-Gln+morphine also elevated extracellular serotonin concentrations although the magnitude of the response did not differ significantly from the effect of Gly-Gln or morphine, given alone suggesting that Gly-Gln suppressed morphine induced serotonin efflux. Gly-Gln abolished the morphine-induced rise in extracellular GABA concentrations but had no effect on extracellular GABA when given alone to otherwise untreated animals. These data show that Gly-Gln stimulates NAc serotonin efflux and, together with earlier studies, support the hypothesis that Gly-Gln inhibits the rewarding effects of morphine by modulating morphine induced dopamine, GABA and serotonin efflux in the NAc.


Subject(s)
Dipeptides/administration & dosage , Morphine/administration & dosage , Narcotics/administration & dosage , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Serotonin/metabolism , gamma-Aminobutyric Acid/metabolism , Animals , Injections, Intraventricular , Male , Rats , Rats, Sprague-Dawley
3.
J Neuroimmunol ; 285: 94-100, 2015 Aug 15.
Article in English | MEDLINE | ID: mdl-26198924

ABSTRACT

This study tested the hypothesis that lipopolysaccharide (LPS) lowers arterial pressure through two different mechanisms depending on the dose. Previously, we found that a low hypotensive dose of LPS (1mg/kg) lowers arterial pressure by activating vagus nerve afferents. Here we report that hypotension evoked by high dose LPS (15mg/kg) can be prevented by injecting lidocaine into the OVLT but not by vagotomy or inactivation of the NTS. The hypotension produced by both LPS doses was correlated with elevated extracellular norepinephrine concentrations in the POA and prevented by blocking alpha-adrenergic receptors. Thus, initiation of endotoxic hypotension is dose-related, mechanistically.


Subject(s)
Arterial Pressure/physiology , Endotoxemia/physiopathology , Hypotension/physiopathology , Lipopolysaccharides/administration & dosage , Lipopolysaccharides/toxicity , Organum Vasculosum/physiology , Animals , Arterial Pressure/drug effects , Dose-Response Relationship, Drug , Endotoxemia/chemically induced , Hypotension/chemically induced , Male , Organum Vasculosum/drug effects , Rats , Rats, Sprague-Dawley
4.
Naunyn Schmiedebergs Arch Pharmacol ; 381(5): 467-75, 2010 May.
Article in English | MEDLINE | ID: mdl-20349045

ABSTRACT

Glycyl-glutamine (Gly-Gln) is an endogenous dipeptide that is synthesized from beta-endorphin post-translationally. Previously, we showed that Gly-Gln prevents acquisition of morphine-conditioned place preference, a behavioral test of morphine reward, but does not interfere with morphine analgesia. In this study, we tested the hypothesis that Gly-Gln inhibits morphine reward by blocking morphine-induced dopamine efflux in the nucleus accumbens (NAc). Extracellular dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) were sampled by microdialysis and analyzed by high-performance liquid chromatography with electrochemical detection. Guide cannulas were implanted in the right NAc and left lateral ventricle of male Sprague-Dawley rats stereotaxically. Approximately 24 h later, a microdialysis probe was inserted into the NAc and perfused at 1 microl/min. Gly-Gln (1, 3, 30, or 100 nmol/5 microl) or saline was administered intracerebroventricularly, morphine (2.5 mg/kg) was injected intraperitoneally (i.p.) 2 min later, and extracellular dopamine and DOPAC were sampled at 20-min intervals. Morphine administration increased extracellular dopamine concentrations by approximately 600% within 40 min. Gly-Gln pretreatment inhibited the rise in extracellular dopamine in a dose-related manner; the lowest significantly inhibitory dose was 1 nmol. Gly-Gln also inhibited the morphine-induced rise in extracellular DOPAC concentrations but did not affect extracellular dopamine or DOPAC in control animals. Gly-Gln (100 nmol/5 microl) prevented morphine-induced dopamine efflux in rats treated with morphine chronically (10 mg/kg, i.p. twice daily for 6 days), although it did not affect DOPAC concentrations significantly. These data support the hypothesis that Gly-Gln abolishes the rewarding effect of morphine by inhibiting the ability of morphine to stimulate dopamine release in the NAc.


Subject(s)
Analgesics, Opioid/pharmacology , Dipeptides/pharmacology , Dopamine/metabolism , Morphine/pharmacology , 3,4-Dihydroxyphenylacetic Acid/metabolism , Analgesics, Opioid/antagonists & inhibitors , Animals , Dipeptides/administration & dosage , Dose-Response Relationship, Drug , Male , Microdialysis , Morphine/antagonists & inhibitors , Nucleus Accumbens/drug effects , Nucleus Accumbens/metabolism , Rats , Rats, Sprague-Dawley , Reward , Time Factors
5.
Shock ; 32(6): 614-20, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19295473

ABSTRACT

It is widely assumed that LPS lowers arterial pressure during sepsis by stimulating release of TNF-alpha and other vasoactive mediators from macrophages. However, recent data from this and other laboratories have shown that LPS hypotension can be prevented by inhibiting afferent impulse flow in the vagus nerve, by blocking neuronal activity in the nucleus of the solitary tract, or by blocking alpha-adrenergic receptors in the preoptic area/anterior hypothalamic area (POA). These findings suggest that the inflammatory signal is conveyed from the periphery to the brain via the vagus nerve, and that endotoxic shock is mediated through a central mechanism that requires activation of POA neurons. In the present study, we tested whether central cannabinoid 1 (CB1) receptors participate in the control of arterial pressure during endotoxemia based on evidence that hypothalamic neurons express CB1 receptors and synthesize the endogenous CB anandamide. We found that intracerebroventricular administration of rimonabant, a CB1 receptor antagonist, inhibited the fall in arterial pressure evoked by LPS significantly in both conscious and anesthetized rats. Rimonabant attenuated both the immediate fall in arterial pressure evoked by LPS and the second, delayed hypotensive phase that leads to tissue ischemia and death. Rimonabant also prevented the associated LPS-induced rise in extracellular fluid norepinephrine concentrations in the POA. Furthermore, rimonabant attenuated the associated increase in plasma TNF-alpha concentrations characteristic of the late phase of endotoxic hypotension. These data indicate that central CB1 receptors may play an important role in the initiation of endotoxic hypotension.


Subject(s)
Anterior Hypothalamic Nucleus/drug effects , Endotoxins/metabolism , Hypotension/prevention & control , Norepinephrine/metabolism , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Animals , Anterior Hypothalamic Nucleus/physiopathology , Arachidonic Acids/pharmacology , Blood Pressure , Endocannabinoids , Hypotension/drug therapy , Lipopolysaccharides/metabolism , Macrophages/metabolism , Male , Neurons/metabolism , Piperidines/pharmacology , Polyunsaturated Alkamides/pharmacology , Pyrazoles/pharmacology , Rats , Rats, Sprague-Dawley , Rimonabant , Tumor Necrosis Factor-alpha/blood
6.
J Neuroimmunol ; 203(1): 39-49, 2008 Oct 15.
Article in English | MEDLINE | ID: mdl-18653249

ABSTRACT

We recently reported that the preoptic anterior hypothalamic area (POA) mediates the hypotensive response evoked by lipopolysaccharide (LPS). In this study, we investigated how the inflammatory signal induced by LPS reaches the POA. Subdiaphragmatic vagotomy and abdominal perivagal lidocaine administration, or lidocaine injection into the nucleus tractus solitarius (NTS) prevented LPS hypotension. Microinjection of the alpha-adrenergic receptor antagonist phentolamine into the POA, blocked initiation of the hypotensive response and prevented the late decompensatory phase. These data suggest that LPS hypotension is mediated by the vagus nerve which conveys the signal to the NTS and, in turn, stimulates norepinephrine release within the POA.


Subject(s)
Hypotension/immunology , Hypotension/physiopathology , Preoptic Area/physiopathology , Receptors, Adrenergic, alpha/metabolism , Solitary Nucleus/physiopathology , Vagus Nerve/physiopathology , Acute Disease , Adrenergic alpha-Antagonists/pharmacology , Anesthetics, Local/pharmacology , Animals , Hypotension/chemically induced , Lidocaine/pharmacology , Lipopolysaccharides/pharmacology , Male , Phentolamine/pharmacology , Preoptic Area/drug effects , Rats , Rats, Sprague-Dawley , Shock, Septic/chemically induced , Shock, Septic/immunology , Shock, Septic/physiopathology , Signal Transduction/immunology , Vagotomy , Vagus Nerve/drug effects
7.
Shock ; 29(2): 232-7, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18386391

ABSTRACT

The mechanism responsible for the initiation of endotoxic hypotension is not fully understood, although it is often attributed to a direct effect of LPS and other vasoactive mediators on the vasculature. Alternatively, recent evidence raises the possibility that endotoxic hypotension may be initiated through a central mechanism. Previous studies have shown that LPS initiates fever, sickness behavior, and other aspects of the inflammatory response through a neural pathway that sends peripheral inflammatory signals to the preoptic anterior hypothalamic area (POA). It is also well known that the POA plays a role in the regulation of cardiovascular function, but its involvement in LPS-induced hypotension has not been examined previously. Therefore, the aim of the present paper was to investigate whether the initial abrupt fall in arterial pressure evoked by LPS in septic shock is mediated by the POA. LPS (1 mg/kg, i.v.) administration to halothane-anesthetized or conscious rats lowered arterial blood pressure by 24.8+/-2.9 and 25.1+/-5.8 mmHg, respectively. Bilateral lidocaine (2%; 1 microL) injection into the POA, but not the lateral hypothalamus, prevented the hypotension evoked by LPS entirely in both anesthetized and conscious animals. Remarkably, this blockade significantly inhibited the second, delayed fall in arterial pressure induced by LPS, and simultaneously decreased TNF-alpha plasma levels. Together, these data indicate that the initial phase of endotoxic hypotension is mediated by the POA and suggest that the initiation of the hypotensive response induced by LPS can be essential for the development of the late fall in blood pressure.


Subject(s)
Anterior Hypothalamic Nucleus/drug effects , Blood Pressure/drug effects , Hypotension/physiopathology , Lipopolysaccharides/toxicity , Animals , Anterior Hypothalamic Nucleus/physiopathology , Hypotension/chemically induced , Hypotension/prevention & control , Lidocaine/pharmacology , Male , Rats , Rats, Sprague-Dawley , Tumor Necrosis Factor-alpha/blood
9.
Neurourol Urodyn ; 25(7): 802-7, 2006.
Article in English | MEDLINE | ID: mdl-16894613

ABSTRACT

PURPOSE: Dextromethorphan (DXM) is a cough-suppressing ingredient in a variety of over-the-counter cough and cold medications. Dextromethorphan elevates the threshold for coughing primarily through a central mechanism. At doses recommended for treating coughs the drug is safe and effective. At much higher doses, DXM produces dissociative effects similar to those of phencyclidine and ketamine. Opioid analgesics structurally related to DXM also inhibit bladder contractions and produce urinary retention through a non-opioid mechanism. This study evaluated the direct effects of DXM on in vitro contractile responses of rat and mouse urinary bladders. METHODS: Male rats and mice were anaesthetized and their bladders removed. Bladder strips were suspended in 15 ml oxygenated Tyrode's solution containing glucose. Bladder strip contractions were evoked by field stimulation (FS), carbachol or elevated KCl concentrations and contractile responses recorded. The strips were then exposed to 3 microM (DXM) for 30 min and re-stimulated. This sequence was repeated at 10, 30, and 100 microM DXM. RESULTS: (a) The rat bladder generated significantly greater tension than the mouse bladder. (b) Dextromethorphan produced a dose-dependent inhibition of the response to FS that was approximately equal for rat and mouse bladders. FS at 8 or 32 Hz was significantly more sensitive to DXM inhibition than 2 Hz. (c) The response to carbachol was more sensitive to inhibition by DXM than the responses to FS or KCl. CONCLUSIONS: These results demonstrate that DXM inhibits bladder contractions in vitro and that mouse and rat bladders are affected to approximately the same extent.


Subject(s)
Dextromethorphan/pharmacology , Urinary Bladder/drug effects , Animals , Carbachol/pharmacology , Electric Stimulation , In Vitro Techniques , Male , Mice , Muscarinic Agonists/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Potassium Chloride/pharmacology , Rats , Rats, Sprague-Dawley , Urodynamics/drug effects
10.
Brain Res ; 1070(1): 45-55, 2006 Jan 27.
Article in English | MEDLINE | ID: mdl-16403465

ABSTRACT

Severe blood loss lowers arterial pressure through a central mechanism that is thought to include opioid neurons. In this study, we investigated whether hemorrhage activates proopiomelanocortin (POMC) neurons by measuring Fos immunoreactivity and POMC mRNA levels in the medial basal hypothalamus. Hemorrhage (2.2 ml/100 g body weight over 20 min) increased the number of Fos immunoreactive neurons throughout the rostral-caudal extent of the arcuate nucleus, the retrochiasmatic area and the peri-arcuate region lateral to the arcuate nucleus where POMC neurons are located. Double label immunohistochemistry revealed that hemorrhage increased Fos expression by beta-endorphin immunoreactive neurons significantly. The proportion of beta-endorphin immunoreactive neurons that expressed Fos immunoreactivity increased approximately four-fold, from 11.7+/-1.4% in sham-operated control animals to 42.0+/-5.2% in hemorrhaged animals. Hemorrhage also increased POMC mRNA levels in the medial basal hypothalamus significantly, consistent with the hypothesis that blood loss activates POMC neurons. To test whether activation of arcuate neurons contributes to the fall in arterial pressure evoked by hemorrhage, we inhibited neuronal activity in the caudal arcuate nucleus by microinjecting the local anesthetic lidocaine (2%; 0.1 or 0.3 microl) bilaterally 2 min before hemorrhage was initiated. Lidocaine injection inhibited hemorrhagic hypotension and bradycardia significantly although it did not influence arterial pressure or heart rate in non-hemorrhaged rats. These results demonstrate that hemorrhage activates POMC neurons and provide evidence that activation of neurons in the arcuate nucleus plays an important role in the hemodynamic response to hemorrhage.


Subject(s)
Hemorrhage/physiopathology , Hypothalamus/physiopathology , Neurons/metabolism , Pro-Opiomelanocortin/metabolism , Animals , Arcuate Nucleus of Hypothalamus/drug effects , Arcuate Nucleus of Hypothalamus/metabolism , Bradycardia/etiology , Bradycardia/prevention & control , Hemorrhage/complications , Hemorrhage/metabolism , Hypotension/etiology , Hypotension/prevention & control , Hypothalamus/metabolism , Hypothalamus, Middle/metabolism , Immunohistochemistry , Injections , Lidocaine/administration & dosage , Lidocaine/pharmacology , Male , Pro-Opiomelanocortin/genetics , Proto-Oncogene Proteins c-fos/metabolism , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , beta-Endorphin/metabolism
11.
Eur J Pharmacol ; 530(1-2): 95-102, 2006 Jan 13.
Article in English | MEDLINE | ID: mdl-16364288

ABSTRACT

Glycyl-glutamine (Gly-Gln) is an inhibitory dipeptide synthesized from beta-endorphin(1-31). Previously, we showed that Gly-Gln inhibits morphine conditioned place preference, tolerance, dependence and withdrawal. In this study, we tested whether Gly-Gln's inhibitory activity extends to other rewarding drugs, specifically nicotine. Rats were conditioned with nicotine (0.6 mg/kg, s.c.) for four days and tested on day five. Glycyl-glutamine (100 nmol i.c.v.) inhibited acquisition and expression of a nicotine place preference significantly. Cyclo(Gly-Gln) (100 nmol i.c.v. or 25 mg/kg i.p.), a cyclic Gly-Gln derivative, blocked expression of nicotine place preference but Gly-d-Gln (100 nmol i.c.v.) was ineffective. To study nicotine withdrawal, rats were treated with nicotine (9 mg/kg/day) for seven days and conditioned place aversion was induced with mecamylamine (1 mg/kg, s.c.). Glycyl-glutamine blocked acquisition of place aversion to mecamylamine but not U50,488, a kappa opioid receptor agonist. Glycyl-glutamine thus inhibits the rewarding effects of nicotine and attenuates withdrawal in nicotine dependent rats.


Subject(s)
Conditioning, Psychological/drug effects , Dipeptides/pharmacology , Nicotine/pharmacology , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , Animals , Avoidance Learning/drug effects , Dose-Response Relationship, Drug , Injections, Intraventricular , Injections, Subcutaneous , Male , Mecamylamine/pharmacology , Nicotinic Agonists/pharmacology , Nicotinic Antagonists/pharmacology , Peptides, Cyclic/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, kappa/agonists , Substance Withdrawal Syndrome/prevention & control , Time Factors
12.
Brain Res ; 1058(1-2): 73-81, 2005 Oct 05.
Article in English | MEDLINE | ID: mdl-16212948

ABSTRACT

Opioid peptides and glycyl-glutamine (Gly-Gln) have been implicated in the control of ethanol consumption. A recognized beta-endorphin cleavage product, Gly-Gln, inhibits voluntary alcohol consumption when microinjected into the nucleus accumbens (AcbSh) of P rats. To evaluate the site-specific efficacy of Gly-Gln on ethanol consumption following AcbSh application, ethanol preferring (P) rats were allowed to establish individual baseline ethanol/water consumption utilizing a voluntary self-administration paradigm. Subsequent to baseline ethanol consumption being established, bilateral guide cannulae were stereotaxically implanted +1 mm dorsal to the AcbSh for subsequent Gly-Gln (100 nmol/microl) or saline vehicle (1 microl) injections. Alcohol intake, body weight, and water intake were measured at 24 h post-injection intervals. Unilateral Gly-Gln injections reduced ethanol consumption 35.6% (P < 0.05) from pre-established baseline consumption (6.24 +/- 0.64 g/kg to 4.06 +/- 0.28 g/kg). Bilateral Gly-Gln injections further reduced consumption to 51.9% (6.4 +/- 1.0 g/kg to 3.08 +/- 0.65 g/kg at 24 h (P < 0.01) below established baseline values within 24 h without significant changes in body weight or water consumption. Also, the amino acid constituents of the dipeptide had no influence on ethanol consumption behavior; however, Gly-Gln efficacy was shown to be comparable to central beta-endorphin-(1-27) or intraperitoneal (i.p.) naltrexone-induced suppression of ethanol intake. These data indicate that the AcbSh exhibits a site-specific sensitivity to the suppressive actions of Gly-Gln or beta-endorphin-(1-27) injections that modulate voluntary ethanol consumption in P rats. These findings support the broader concept that select forebrain opioid-responsive neural sites may influence the development or expression of alcohol abuse syndromes in animal models or humans.


Subject(s)
Alcohol-Induced Disorders, Nervous System/drug therapy , Dipeptides/pharmacology , Ethanol/adverse effects , Nucleus Accumbens/drug effects , Alcohol-Induced Disorders, Nervous System/metabolism , Alcohol-Induced Disorders, Nervous System/physiopathology , Alcoholism/drug therapy , Animals , Central Nervous System Depressants/adverse effects , Disease Models, Animal , Genetic Predisposition to Disease/genetics , Narcotic Antagonists/pharmacology , Nucleus Accumbens/metabolism , Nucleus Accumbens/physiopathology , Rats , Rats, Mutant Strains , Receptors, Opioid/agonists , Receptors, Opioid/metabolism , beta-Endorphin/analogs & derivatives , beta-Endorphin/metabolism , beta-Endorphin/pharmacology
13.
J Pharmacol Exp Ther ; 315(2): 949-58, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16079299

ABSTRACT

Glycyl-glutamine (Gly-Gln; beta-endorphin(30-31)) is an endogenous dipeptide synthesized from beta-endorphin(1-31). Previous investigations have shown that Gly-Gln inhibits the cardiovascular and respiratory depression caused by morphine and beta-endorphin(1-31), but it does not interfere with opioid analgesia. In this study, we tested whether Gly-Gln administration would influence morphine-induced conditioned place preference, tolerance, dependence, or withdrawal. For place preference experiments, rats were conditioned with morphine sulfate (2.5 mg/kg i.p.) or saline on alternate days for 6 days and tested on day 7. Glycyl-glutamine (1-100 nmol i.c.v.) pretreatment inhibited acquisition of a conditioned place preference to morphine significantly. Glycyl-glutamine (100 nmol i.c.v.) also blocked expression of a pre-established morphine place preference, but it did not interfere with acquisition of a conditioned place preference to palatable food, and it did not produce place preference or aversion when given alone to morphine-naive animals. To induce antinociceptive tolerance, rats were treated with morphine (10 mg/kg i.p.) twice daily for 7 days, and morphine antinociception was evaluated with the tail-flick test. Glycyl-glutamine (100 nmol i.c.v.) pretreatment delayed the onset of morphine tolerance significantly and partially reversed pre-established tolerance. Morphine dependence and withdrawal were assessed by measuring naloxone-precipitated withdrawal symptoms. Glycyl-glutamine inhibited the development of morphine dependence when given to rats twice daily immediately before they received morphine (10 mg/kg i.p.) and suppressed withdrawal symptoms of rats with subcutaneously implanted morphine pellets when administered 5 min before withdrawal was induced with naloxone. Glycyl-glutamine thus attenuates morphine-induced conditioned place preference, tolerance, dependence, and withdrawal without compromising morphine analgesia.


Subject(s)
Analgesics, Opioid/antagonists & inhibitors , Conditioning, Operant/drug effects , Dipeptides/pharmacology , Morphine Dependence/prevention & control , Morphine/antagonists & inhibitors , Substance Withdrawal Syndrome/prevention & control , beta-Endorphin/pharmacology , Analgesics, Opioid/pharmacology , Animals , Behavior, Animal/drug effects , Dipeptides/administration & dosage , Dipeptides/chemistry , Dose-Response Relationship, Drug , Drug Tolerance , Food , Injections, Intraventricular , Male , Morphine/pharmacology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Rats , Rats, Sprague-Dawley , Reinforcement, Psychology , beta-Endorphin/chemistry
14.
Brain Res ; 1029(1): 124-30, 2004 Dec 10.
Article in English | MEDLINE | ID: mdl-15533324

ABSTRACT

This study investigated whether the lateral hypothalamus (LH) contributes to the depressor response evoked by somato-visceral nociception. Lidocaine (2%; 0.1, 0.3 or 1.0 microl) or muscimol (0.34 nmol; 0.5 microl) was microinjected into the rostral LH of halothane-anesthetized rats bilaterally and somato-visceral nociception was induced 2 min later by injecting 5% acetic acid (0.5 ml) intraperitoneally. Lidocaine and muscimol inhibited the hypotension and bradycardia caused by somato-visceral nociception significantly without affecting cardiovascular function in normotensive animals.


Subject(s)
Bradycardia/physiopathology , GABA Agonists/administration & dosage , Homocysteine/analogs & derivatives , Hypotension/physiopathology , Hypothalamic Area, Lateral/drug effects , Muscimol/administration & dosage , Animals , Bradycardia/etiology , Cardiovascular Physiological Phenomena , Homocysteine/administration & dosage , Hypotension/etiology , Male , Microinjections , Pain/complications , Pain/physiopathology , Rats , Rats, Sprague-Dawley
15.
Brain Res ; 1019(1-2): 237-45, 2004 Sep 03.
Article in English | MEDLINE | ID: mdl-15306258

ABSTRACT

This study tested the hypothesis that the ventrolateral column of the midbrain periaqueductal gray (vlPAG) region mediates the hypotension and bradycardia evoked by visceral nociception. To test this, the local anesthetic lidocaine (2%; 0.5 microl) was microinjected into the vlPAG of halothane-anesthetized rats bilaterally and visceral nociception was induced 2 min later by injecting 5% acetic acid (0.5 ml) intraperitoneally. Acetic acid injection caused an abrupt fall in arterial pressure (-12.2+/-2.1 mm Hg) and heart rate (-37+/-93 bpm) lasting approximately 15 min. Lidocaine injection into the vlPAG prevented the fall in arterial pressure and heart rate completely. Cobalt chloride (5 mM; 0.2 or 0.5 microl) injection into the vlPAG also prevented nociceptive hypotension but it did not affect the fall in heart rate significantly. Lidocaine pretreatment also inhibited the depressor response caused by intramuscular formalin (5%; 0.2 ml) administration, a model of deep somatic nociception, although it did not prevent the response completely. To determine if opioid receptors mediate the response, selective mu, delta or kappa opioid receptor antagonists were microinjected into the vlPAG 5 min before intraperitoneal (ip) acetic acid administration. Naltrindole, a delta receptor antagonist, inhibited the response significantly but mu and kappa antagonists were completely ineffective. Lidocaine and naltrindole had no effect when injected into the dorsolateral PAG and did not influence cardiovascular function when injected into the vlPAG of saline treated control animals. These data support the hypothesis that the vlPAG mediates the depressor response evoked by visceral nociception and indicate that delta opioid receptors participate in the response.


Subject(s)
Hypotension/physiopathology , Pain Measurement/methods , Periaqueductal Gray/physiology , Receptors, Opioid, delta/physiology , Animals , Heart Rate/drug effects , Heart Rate/physiology , Male , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects , Periaqueductal Gray/drug effects , Rats , Rats, Sprague-Dawley , Receptors, Opioid, delta/antagonists & inhibitors
16.
Neurosci Lett ; 363(2): 116-9, 2004 Jun 10.
Article in English | MEDLINE | ID: mdl-15172097

ABSTRACT

This study tested the hypothesis that morphine and other opiates cause urinary retention by activating mu opioid receptors in the midbrain periaqueductal gray (PAG) region. Selective mu, delta and kappa receptor agonists were microinjected into the PAG of urethane-anesthetized rats and the amplitude and incidence of bladder contractions were recorded during continuous saline infusion. Arterial pressure was monitored through a femoral artery catheter. Microinjection of the mu receptor agonist DAMGO into the ventrolateral PAG (vlPAG) suppressed volume-evoked bladder contractions completely. Bladder contractions ceased within 5 min of DAMGO injection and remained essentially undetectable for the rest of the 20 min recording period. Microinjection of the delta receptor agonist DPDPE into the vlPAG did not significantly affect either the amplitude of bladder contractions or the time interval separating contractions. The kappa receptor agonist U-69593 caused no discernible change in amplitude but increased the interval between bladder contractions significantly. Microinjection of DAMGO, DPDPE or U-69593 into the lateral or dorsolateral PAG columns was ineffective. DAMGO injection into the vlPAG increased arterial pressure whereas DPDPE and U-69593 produced a small but significant depressor response. These data support the hypothesis that mu and kappa receptors in the vlPAG participate in the micturition reflex.


Subject(s)
Periaqueductal Gray/metabolism , Receptors, Opioid, mu/metabolism , Reflex/physiology , Urination/physiology , Administration, Intravesical , Anesthetics/pharmacology , Animals , Benzeneacetamides/pharmacology , Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology , Enkephalin, D-Penicillamine (2,5)-/pharmacology , Female , Microinjections , Morphine/pharmacology , Muscle Contraction/drug effects , Muscle Contraction/physiology , Narcotics/pharmacology , Periaqueductal Gray/drug effects , Pyrrolidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, kappa/drug effects , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/drug effects , Reflex/drug effects , Sodium Chloride/administration & dosage , Urinary Bladder/innervation , Urinary Bladder/physiopathology , Urination/drug effects
17.
Clin Exp Pharmacol Physiol ; 30(9): 640-2, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12940881

ABSTRACT

1. Severe blood loss initially lowers arterial pressure through a central mechanism that is thought to involve opioid and cholinergic neurons. The present study tested the hypothesis that simultaneous administration of a cholinergic agonist and an opioid receptor antagonist would produce a synergistic effect in the treatment of haemorrhage. Specifically, we tested whether choline, a precursor of acetylcholine, potentiates the pressor effect of the beta-endorphin derived peptide glycyl-glutamine (Gly-Gln) or the opioid receptor antagonist naloxone following acute haemorrhage. 2. Conscious rats were treated intracerebroventricularly (i.c.v.) with choline chloride (180 nmol) alone or combined with Gly-Gln (10 nmol) or naloxone (10 nmol) 2 min after blood withdrawal (2.5 mL/100 g bodyweight over 20 min) was completed; mean arterial pressure and heart rate were monitored for 30 min. 3. Combined treatment with choline and Gly-Gln elevated mean arterial pressure but did not affect heart rate significantly. Choline and Gly-Gln had no effect on cardiovascular function when administered alone to haemorrhaged rats or when given together to normotensive animals. Choline also potentiated the pressor and tachycardic effect of naloxone in haemorrhaged rats. 4. These data show that choline potentiates the pressor effect of Gly-Gln and naloxone in haemorrhaged rats.


Subject(s)
Blood Pressure/drug effects , Choline/therapeutic use , Dipeptides/therapeutic use , Hemorrhage/drug therapy , Naloxone/therapeutic use , Pressoreceptors/physiology , Animals , Blood Pressure/physiology , Choline/pharmacology , Dipeptides/pharmacology , Drug Synergism , Female , Heart Rate/drug effects , Heart Rate/physiology , Hemorrhage/physiopathology , Male , Naloxone/pharmacology , Pressoreceptors/drug effects , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...